MULTIPLE MYELOMA

In the first article of a 2-part series, Joshua Richter, MD, discussed how the triplet therapy of isatuximab, carfilzomib and dexamethasone, has impacted treatment considerations for patients with high-risk multiple myeloma.

Clark DuMontier, MD, discusses the main takeaways from his presentation on treatment intensity and frailty in newly diagnosed patients with multiple myeloma given at the 20th International Myeloma Society Annual Meeting.

Rafael Fonseca, MD, envisions a future where bispecific antibodies and CAR T-cell therapy, currently used in advanced stages of multiple myeloma treatment, can offer potential cure for patients, and emphasizes the importance of advocating for their broader application in community settings.

An expert oncologist discusses novel treatments for relapsed/refractory multiple myeloma presented at recent meetings, highlighting a study on elranatamab, a new compound targeting BCMA, and trials including the LINKER-MM1 study on linvoseltamab.

Rafael Fonseca, MD, discusses the sequencing of CAR-T and bispecific antibodies in patients with relapsed/refractory multiple myeloma and tailoring treatment based on prior medical history for elderly and frail individuals.

Dr Fonseca shares findings from the MonumenTAL-1 trial presented at ASCO 2023, suggesting potentially reduced infection rates in patients with relapsed/refractory multiple myeloma receiving talquetamab relative to BCMA-targeted agents.

In the second article of this 2-part series, Sikander Ailawadhi, MD, discusses how understanding the safety profile of the bispecific antibody teclistamab allows for physicians to treat and monitor their patients in a better way for them.

The role of risk stratification in treatment decisions for patients with newly diagnosed, transplant eligible multiple myeloma vs newly diagnosed, transplant ineligible multiple myeloma was explored by Natalie S. Callander, MD.

Dr Rafael Fonesca reviews data from the TriMM-2 study presented at ASCO 2023 investigating combination talquetamab plus daratumumab for patients with relapsed/refractory multiple myeloma, highlighting a 78% response rate to talquetamab, but noting side effects like CRS and infections.

Rafael Fonseca, MD, emphasizes the considerations of selecting therapies targeting specific markers like BCMA and GPRC5D in patients with relapsed/refractory multiple myeloma, such as prior exposures, efficacy, and potential side effects.

While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.

In a discussion with Targeted Oncology, David Dingli, MD, PhD, looks at how the use of step-up dosing with tecalistimab helped avoid many serious adverse events.

Dr Fonseca discusses the prognosis of a patient with relapsed/refractory multiple myeloma, noting the patient's history with treatments like venetoclax and dexamethasone, and the ultimate decision to switch to talquetamab, a GPRC5D-directed bispecific antibody.

Rafael Fonseca, MD, presents the clinical case of a 66-year-old man with relapsed/refractory multiple myeloma for review.

In an interview with Targeted Oncology, Dan T. Vogl, MD, MSCE, discussed a phase 1 study which evaluated modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.

Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.

The importance of patient education, remote monitoring, and infection prophylaxis in the safe administration of bispecific antibody therapy for relapsed/refractory multiple myeloma.

David M. Dingli, MD, PhD, discusses the advantages and considerations of CAR T-cell therapy versus bispecific antibodies for relapsed/refractory multiple myeloma, helping patients make informed treatment decisions.

Expert perspective on teclistamab, a bispecific antibody, in the context of multiple myeloma treatment, discussing its potential benefits and associated considerations.

An exploration of the landscape of immunologic therapies and alternative approaches for relapsed/refractory multiple myeloma, including bispecific antibodies, XPO1 inhibitors, venetoclax, and more.

David M. Dingli, MD, PhD, a hematologist at Mayo Clinic, as he discusses a challenging case of pentarefractory multiple myeloma in a 76-year-old patient and explores novel treatment options.

Joshua Richter, MD, discusses the available combination therapies for patients with early relapsed/refractory multiple myeloma using anti-CD38 monoclonal antibodies.

While there was no significant difference in overall survival between the daratumumab and control groups, safety profile results and follow-up data support daratumumab’s continued evaluation in relapsed/refractory multiple myeloma.

In the first article of a 2-part series, Sikander Ailawadhi, MD, looks at how the field has changed for treatment of patients with relapsed/refractory multiple myeloma and how recent study results with teclistamab show the impact of targeting BCMA in these patients.